SXTC - China SXT Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.8500
-0.1600 (-3.19%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.0100
Open5.0100
Bid0.0000 x 2900
Ask5.9300 x 800
Day's Range4.7800 - 5.1595
52 Week Range3.6180 - 23.3500
Volume237,338
Avg. Volume323,575
Market Cap109.35M
Beta (3Y Monthly)N/A
PE Ratio (TTM)69.29
EPS (TTM)0.0700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire9 days ago

    China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing

    TAIZHOU, China , April 17, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ( NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, ...

  • PR Newswire24 days ago

    China SXT Pharmaceuticals, Inc. Receives National High-tech Enterprise Qualification

    TAIZHOU, China, Apr. 2, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc.  (the "Company") (SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today that its VIE subsidiary, Jiangsu Suxuantang Pharmaceutical Co., Ltd. ("Taizhou Suxuantang"), has been certified as National High-tech Enterprise (the "Certification") by the Ministry of  Science and Technology of the PRC. The Certification is valid for three years and allows Taizhou Suxuantang to enjoy a preferential income tax rate of 15% versus the standard rate of 25%.

  • PR Newswire29 days ago

    China SXT Pharmaceuticals, Inc. Announces Financial Results for the Six Months Ended September 30, 2018

    TAIZHOU, China , March 28, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc.  (the "Company") (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, ...

  • ACCESSWIRE3 months ago

    4 Healthcare Stocks Looking To Finish Strong On Wednesday (1/30/19)

    Premier Health Group (PHGRF) (PHGI), China SXT Pharmaceuticals Inc (SXTC), eHealth Inc (EHTH), and Ekso Bionics Holdings Inc (EKSO) represent four healthcare companies determined to provide the best quality of care for consumers in need. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments meant to demonstrate to both investors and consumers that the Company is determined to invest in the future of its customers. Premier Health Group (PHGRF) (PHGI) announced earlier this week that, further to its new release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • PR Newswire4 months ago

    China SXT Pharmaceuticals, Inc. Announces Final Closing of Initial Public Offering

    TAIZHOU, China and NEW YORK, Jan. 4, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (the "Company") (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), today announced the final closing of its initial public offering on January 3, 2019. Together with the first closing on December 31, 2018, the Company raised approximately $10.2 million in gross proceeds, before deducting underwriting discounts, commissions and other offering expenses, by issuing 2,546,275 ordinary shares at a public offering price of $4.00 per share. The shares are scheduled to commence trading on the NASDAQ Capital Market today at around 2:05 p.m. ET under the ticker symbol "SXTC".